Andrea Nguyen, DMSc, MPAS, PA-C

Segment summary: In the final episode of the series, the discussion turns to therapies currently in development for CSU. The agent generating the most excitement is an investigational anti-Kit monoclonal antibody, the first treatment designed to directly bind and eliminate mast cells rather than simply blocking their activation. Early trial data show strong efficacy, but the drug carries a notable cosmetic side effect: because it also affects melanocytes, a substantial proportion of patients experience hair whitening and skin depigmentation, a tradeoff the panel notes is worth discussing openly with patients before treatment begins.

Emerging Therapies on the Horizon for CSU

This may become the most effective option available once approved, though tolerance for the side effect will vary widely; some patients may be far less concerned about changes in hair or skin pigmentation than others. Beyond this mast cell-depleting agent, a broader pipeline of CSU candidates is moving through preclinical and early clinical phases, and while not all will ultimately succeed, this is characterized as an unusually exciting period for the field. Development also continues within the oral BTK inhibitor class, with next-generation, even more selective agents already being explored.

The discussion closes with reflection on how far CSU management has progressed, from a historically underdiagnosed and undertreated condition to one with multiple safe, effective, and rapidly expanding treatment options. Between the therapies already available and the candidates still in the pipeline, clinicians and patients alike have genuine reason for optimism, and the pace of innovation in CSU shows little sign of slowing as additional mechanisms of action continue to move through clinical development. Thank you for watching this HCPLive Peers & Perspectives series on chronic spontaneous urticaria. Please subscribe to our enewsletter for information on upcoming video series.

Videos

In the final episode of the series, the discussion turns to therapies currently in development for CSU.

Segment summary: In this episode titled “Building Therapeutic Alliance and Addressing Access Barriers in CSU,” the panel focuses on practical strategies for empowering both patients and clinicians earlier in the CSU care journey. Effective communication is framed around three things patients want when they present with CSU: relief of symptoms, an explanation for why this happened, and a sense of control over their condition. Confidently explaining that CSU is autoimmune rather than allergic is emphasized, since most patients arrive assuming a food allergy is to blame.

Building Therapeutic Alliance and Addressing Access Barriers in CSU

Rather than directly contradicting that belief, the panel validates it by introducing newer evidence that diet does play a role, but through salicylate sensitivity rather than true allergy; patients are advised to avoid NSAIDs, aspirin, and other salicylate-containing products, acetaminophen remains safe, and following a low-salicylate diet has been shown in a randomized, placebo-controlled trial to reduce disease severity. This reframing builds a therapeutic alliance by addressing all three of the patient’s underlying concerns without delaying initiation of effective therapy, while still allowing referral to allergy specialists for patients who request it.

The conversation closes on real-world access barriers: it is considerably easier to secure the dermatology-focused biologic and the oral BTK inhibitor for patients because office staff are well versed in those approval processes, whereas the allergy-focused anti-IgE biologic is comparatively harder to navigate due to limited internal experience with its support programs. Both speakers note the added logistical burden of mandated post-injection observation periods for the biologics, despite the absence of any reported anaphylaxis cases in CSU patients receiving these therapies. The episode reinforces that addressing patient concerns directly and removing avoidable access friction are just as important to good outcomes as selecting the right medication. In the next episode, “Emerging Therapies on the Horizon for CSU,” the panel previews investigational agents in the CSU pipeline, including a novel mast cell-depleting antibody and next-generation BTK inhibitors.

In this episode titled “Building Therapeutic Alliance and Addressing Access Barriers in CSU,” the panel focuses on practical strategies for empowering both patients and clinicians earlier in the CSU care journey.

Segment summary: This episode titled “Evaluating Biologic Options and Monitoring Response in CSU,” focuses on outcomes data for the biologic targeting the IL-4 receptor pathway, dupilumab. Over a 24-week horizon, overall efficacy is broadly comparable to remibrutinib, but the path to improvement looks different: the BTK inhibitor produces a sharp separation from placebo within about four weeks, while the biologic shows a more gradual, steady improvement that takes closer to four months to reach a similar plateau.

Evaluating Biologic Options and Monitoring Response in CSU

Dupilumab’s decade-long track record is highlighted, with millions of patients treated across other approved indications, and it appears even better tolerated in urticaria than in atopic dermatitis, where conjunctivitis is a known side effect that does not appear in CSU patients. As with the other advanced options, about two-thirds of patients do well while roughly one-third require a change in therapy. Patient preference ultimately hinges on desired speed of onset, route of administration, comorbid atopic conditions, and, for younger patients, age-based approval differences, noting dupilumab’s recent approval down to age two, though both speakers acknowledge seeing few or no pediatric CSU cases in their own practices.

On monitoring, a consistent 12-week follow-up across all three advanced therapy classes is used to decide whether to continue or switch, since waiting longer only prolongs patient suffering if a drug is not working. It is also routine to confirm that patients have not quietly discontinued their background antihistamine, which can mimic treatment failure. Finally, with three effective advanced options now available, cyclosporine use has become rare, with only one current patient remaining on it as an adjunct after a partial response to biologic therapy. In the next episode, “Building Therapeutic Alliance and Addressing Access Barriers in CSU,” the panel shares strategies for educating patients about the autoimmune and dietary aspects of CSU and discusses real-world coverage and access challenges.

This episode titled “Evaluating Biologic Options and Monitoring Response in CSU,” focuses on outcomes data for the biologic targeting the IL-4 receptor pathway, dupilumab.

Segment summary: With three advanced therapy classes now available, this episode focuses on the clinical trial evidence and safety profile supporting the oral BTK inhibitor option. The pivotal phase 3 trials are described as large, well-designed studies in which patients remained on a stable antihistamine dose throughout, reflecting real-world practice of adding rather than replacing background therapy. The standout finding is speed: response curves separate sharply from placebo almost immediately.

Trial Data and Safety of Remibrutinib for CSU

Using rounded, simplified figures for patients, roughly half achieve excellent control, about two-thirds do well overall, and roughly one-third will not respond adequately to a given agent and require a switch, a pattern that holds true across all three advanced therapy classes. The meaningful difference between options is not ultimate efficacy but how quickly that efficacy arrives. Many patients, having previously been treated with oral corticosteroids, find an oral pill conceptually easier to accept than starting an injectable, even though injectable therapies generally carry excellent safety profiles, and the panel stresses reminding patients not to discontinue antihistamines prematurely, continuing them until clinical clearance is achieved.

The conversation closes on safety, specifically the labeled bleeding warning, which is clarified to refer almost entirely to easy bruising, with nosebleeds in only about 1% of patients and no reports of serious hemorrhage; holding the drug for three days before and after procedures is advised as a precaution. This favorable profile is contrasted with older, less selective BTK inhibitors used in oncology, which carry meaningful atrial fibrillation and bleeding risks, underscoring that this newer, highly selective agent behaves very differently from its predecessors in the same drug class. In the next episode, “Evaluating Biologic Options and Monitoring Response in CSU,” the panel compares onset speed and tolerability for a biologic targeting the IL-4 receptor pathway and outlines an approach to monitoring treatment response.

With three advanced therapy classes now available, this episode focuses on the clinical trial evidence and safety profile supporting the oral BTK inhibitor option.

Andrea Nguyen, DMSc, MPAS, PA-C

Articles